Detalhe da pesquisa
1.
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
Cell
; 157(2): 369-381, 2014 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24703711
2.
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.
Cell
; 148(1-2): 59-71, 2012 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22265402
3.
How I treat refractory and relapsed acute myeloid leukemia.
Blood
; 143(1): 11-20, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944143
4.
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
N Engl J Med
; 386(16): 1519-1531, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443108
5.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
6.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
; 141(2): 156-167, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714312
7.
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol
; 204(3): 877-886, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952982
8.
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
Blood
; 139(3): 323-332, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34111285
9.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood
; 140(15): 1674-1685, 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960871
10.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
11.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood
; 139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995344
12.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood
; 140(12): 1345-1377, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797463
13.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood
; 140(21): 2228-2247, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130297
14.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
15.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med
; 383(26): 2526-2537, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369355
16.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
17.
Analysis, identification and visualization of subgroups in genomics.
Brief Bioinform
; 22(3)2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954413
18.
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Blood
; 137(22): 3093-3104, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598693
19.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
20.
Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Mol Cancer
; 21(1): 166, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986270